Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Sometimes no treatment is the right option for low-risk prostate cancer

27.03.2006


New study to explore if low-risk patients can avoid or postpone therapy safely and effectively



When Houston restaurateur Tony Masraff was diagnosed with early-stage prostate cancer, his life was packed with dancing, running marathons, playing tennis, gardening, leading a successful business and spending time with his family.

But it wasn’t until his doctor at The University of Texas M. D. Anderson Cancer Center advised "watchful waiting" as an option to invasive surgery and radiation that he realized he could continue his active life - free of treatment side effects, but with the cancer.


Masraff is one of about 200 men diagnosed with low-risk prostate cancer at M. D. Anderson on active surveillance for their disease, having changes monitored through regular Prostate Specific Antigen (PSA) tests, biopsies and check-ups. He also is one of hundreds of thousands of men nationwide who have had their prostate cancer detected by regular PSA tests at such an early stage that managing low-risk disease through surveillance outweighs the risks and possible side effects of treatments.

Now, a new study at M. D. Anderson will follow low-risk patients eligible for watchful waiting to determine if they can avoid or postpone therapy and related side effects, and still live as long as patients who immediately receive invasive therapy. The study will provide key information for the future development of clinical guidelines for watchful waiting.

"With the advent of the PSA test, we see prostate cancer detected much earlier but there is no evidence that early detection means longer survival. Because of the sensitivity of the test, clinically insignificant tumors sometimes are over-diagnosed and patients may, as a consequence, be over-treated with radiation and surgery," said Jeri Kim, M.D., principal investigator of the study and assistant professor in the Department of Genitourinary Medical Oncology at M. D. Anderson.

The study will enroll 650 prostate cancer patients who have been clinically defined either as low risk, or patients with localized prostate cancer who have refused early intervention, or patients with localized cancer who are precluded from therapy due to other serious health conditions. Patients who have had previous treatment for their prostate cancer are not eligible to participate.

Patients will have a biopsy at the beginning of the study to confirm the diagnosis of localized prostate cancer followed by PSA tests and digital rectal exams every six months. The need for additional biopsies will be determined at the end of the first year of surveillance, and participants on the study will be given a transrectal ultrasonography annually to detect any possible changes.

Patients also will be asked to complete a survey on their general health conditions as well as six other short surveys which will be used to monitor diet and behavior as part of related research.

Prostate cancer is one of only a few cancers that can be latent in the body for some time and not require immediate treatment," said Dr. Kim. "Many researchers have documented over the years that men die with their disease rather than from it, and while we need to intervene early, we also need to intervene appropriately with respect to the stage of disease, the man’s age, his health in general and quality of life."

Tony Masraff, now 68 years old, preaches "watchful waiting" to men diagnosed with early prostate cancer and has yet to regret not having a more invasive therapy to rid him of the cancer. He is diligent, however, in keeping his appointments and follow-up tests.

"I decided my quality of life was worth more than having a tumor taken out or radiated," said Masraff. "I don’t worry about my prostate cancer. I really don’t have time to worry about it."

Julie A. Penne | EurekAlert!
Further information:
http://www.mdanderson.org

All articles from Statistics >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>